Imatinib is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, primarily chronic myelogenous leukemia (CLM). This study evaluates clinical outcome and cost-effectiveness of imatinib in CML-patients. A lifetime cost-effectiveness model was developed and Swedish registry data on CML-patients diagnosed 1973-2008 was applied. The data, covering four decades, revealed dramatically improved survival in CML, paralleled by ICER levels generally accepted by authorities.
Leukemia & Lymphoma 2015; 56(5): 1385 - 1391